Change is in the air in the schizophrenia treatment market that was once led by global pharmaceutical companies such as Otsuka Pharmaceutical and Janssen.

Domestic companies are acquiring rights of originals and introducing new products to chase the multinational leaders in the market. In response to the change, the global pharmaceutical companies are also preparing strategies such as adding a new dose to their product line for the first time in 6 years.

◆ Boryung rises to the rank as No.3 after securing ‘Zyprexa’

According to industry sources on the 13th, the schizophrenia treatment market in Korea is estimated to be around ₩200 billion. The market had been l